Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 13/20 | 0.51 |
| ▸ | CDK2 | P24941 | 9/20 | 0.51 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.45 |
| ▸ | PTP4A2 | Q12974 | 1/20 | 0.45 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | TYK2 | P29597 | 2/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4506115 | 0.73 | JAK2 (0.43) | JAK2JAK1TYK2JAK3KIF11 | |
| SCHEMBL13606460 | 0.73 | GSK3B (0.41) | GSK3BCDK2PTP4A3PTP4A2PTP4A1 | |
| SCHEMBL3088202 | 0.70 | GSK3B (0.41) | GSK3BCDK2PTP4A3PTP4A2PTP4A1 | |
| SCHEMBL4351095 | 0.70 | GSK3B (0.41) | GSK3BCDK2PTP4A3PTP4A2PTP4A1 | |
| SCHEMBL16418590 | 0.69 | MCL1 (0.49) | MCL1 | |
| SCHEMBL15123780 | 0.66 | PRKDC (0.60) | JAK2JAK1TYK2JAK3KIF11 | |
| SCHEMBL4902650 | 0.65 | MCL1 (0.46) | GSK3BCDK2PTP4A3PTP4A2PTP4A1 | |
| SCHEMBL3069636 | 0.64 | DPYD (0.42) | GSK3BCDK2MCL1 | |
| SCHEMBL6602865 | 0.63 | IMPDH2 (0.51) | KIF11 | |
| SCHEMBL8957516 | 0.63 | IMPDH2 (0.51) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-7199119-B2 | Antiinflammation agents | AMGEN INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-20040097485-A1 | Antiinflammation agents | TULARIK INC. | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155777-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | GSK3B 1989/4885CDK2 111/4885PTP4A3 3920/4885 |
| US-20040097485-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | GSK3B 1989/4885CDK2 111/4885PTP4A3 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.